Drug · DIN 02243173
DEFINITY
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since August 4, 2009; first marketed February 16, 2002.
- Drug Identification Number (DIN)
- 02243173
- Company (DIN owner)
- Lantheus Mi Canada IncMontreal, Quebec, Canada
- Schedule
- Prescription
- Dosage form
- Suspension
- Route
- Intravenous
- Therapeutic class (ATC)
- Microspheres of phospholipids V08DA04
- Class
- Human
- Record last updated
- June 26, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| PERFLUTREN | 150 MCL | ML |
Notices of Compliance
Health Canada approvals that name this DIN.
- September 29, 2008: NOC 9805New Drug Submission (NDS) · Manufacturer name change
- February 15, 2002: NOC 772New Drug Submission (NDS) · Manufacturer name change
- December 28, 2000: NOC 1371New Drug Submission (NDS)
Recalls and safety alerts that mention it
Health Canada’s recall notices do not carry licence numbers, so these are matched by name: notices whose title or product names “definity”. A notice may cover another product or only some lots: read it to see what it covers.
- Definity (Perflutren Injectable Suspension) - For Health ProfessionalsMay 28, 2008 · Drugs
- Important safety information on Definity (Perflutren Injectable Suspension) - For Health ProfessionalsOctober 19, 2007 · Drugs